Clascoterone for Hair Loss: The First New Mechanism in 30 Years

A topical DHT blocker that works locally in the scalp without measurable systemic absorption. Two Phase 3 trials, 1,465 patients, statistically significant hair regrowth versus placebo. Not FDA-approved yet — filing planned for early 2027 — but the trial package is the strongest new-mechanism story in three decades.

Clascoterone is the active ingredient already sold under the brand name Winlevi for acne. Cosmo Pharmaceuticals, the Dublin-based company that owns it, has spent the last several years running a Phase 3 program to develop the same molecule as a 5% topical solution for male androgenetic alopecia. As of publication, the data package is complete, the 12-month safety follow-up is done, and regulatory submissions to the FDA and EMA are being prepared, with US filing planned for early 2027. If it gets approved, clascoterone would be the first new mechanism of action for pattern hair loss since finasteride was approved in 1997.

How clascoterone works

Clascoterone is a topical androgen receptor inhibitor. It binds to the same receptor that dihydrotestosterone (DHT) binds to inside hair follicle cells, but it does not activate the receptor — it blocks DHT from binding. The end result is similar to what finasteride achieves (blunted DHT signal at the follicle), but by a different route and with a critical difference: finasteride works by lowering the amount of DHT your body makes systemically, while clascoterone works by blocking DHT locally at the site of application without measurable amounts entering the bloodstream.

That distinction is why clascoterone is a genuinely different drug rather than a "topical finasteride." Compounded topical finasteride, which some clinics prescribe, still results in measurable systemic finasteride levels in most users, meaning the systemic side-effect profile (libido, mood, potential post-finasteride syndrome discussion) doesn't fully disappear. Clascoterone's molecule is designed to break down rapidly once it's absorbed — the parent drug barely enters circulation, and its metabolite has minimal androgen receptor activity.

The Phase 3 SCALP data

Cosmo ran two identically designed pivotal trials called SCALP 1 (in the United States) and SCALP 2 (in Europe), with a combined enrollment of 1,465 men with mild-to-moderate male pattern hair loss. Participants applied clascoterone 5% solution twice daily. The primary endpoint was change from baseline in Target-Area Hair Count (TAHC) at 6 months. Topline results were announced in December 2025; 12-month safety and durability results followed in April 2026.

Both trials met their primary endpoints with statistical significance (p<0.05). Patient-reported outcomes — how patients themselves scored their own hair — reached statistical significance in one study and trended positively in the other, meaning the objective density gains generally translated to changes patients noticed. The 12-month follow-up data released in April 2026 showed that patients on continuous clascoterone continued to gain hair through month 12, while those who switched to placebo at month 7 lost some of the gains, which supports the standard hair-loss-drug lesson that these treatments only work as long as you keep using them.

Reading the 539% vs 168% number

The gap between the two trials looks striking, but it's not evidence of one working and the other not — both were positive and both met their endpoints. Relative-improvement percentages amplify small absolute differences when the placebo denominator is low, which is common in short hair-count studies. The clinically meaningful takeaway is that both trials showed statistically significant efficacy across ~1,465 patients, with safety comparable to placebo. That's the strongest hair-loss trial package seen in decades.

Safety — the reason women should pay attention

Across both SCALP trials, treatment-emergent adverse events were similar between clascoterone and vehicle (placebo). Skin irritation was the most common local side effect, similar to what patients report with topical minoxidil. There were no statistically significant signals for sexual dysfunction, mood changes, or other systemic effects that patients associate with oral finasteride and dutasteride. This is the profile you'd expect from a drug that doesn't meaningfully enter circulation.

For men, that shifts the risk-benefit conversation. For women — who are largely locked out of finasteride and dutasteride outside of very specific clinical scenarios because of teratogenicity risk (harm to a developing fetus) — a topical anti-androgen with no measurable systemic exposure is a treatment they've essentially never had access to before. If clascoterone is approved with an indication or off-label pattern of use that includes women with androgen-mediated hair loss (female pattern hair loss with androgenetic features), it may be the single biggest addition to female hair-loss medicine in a generation.

Where clascoterone sits in 2026 — and when it might actually reach patients

Clascoterone as Winlevi has been available for acne since 2020 in the United States and 2022 in Europe. That existing FDA and EMA history should make the AGA approval pathway somewhat shorter than a brand-new molecule — the base safety database is bigger, manufacturing is validated. But the AGA program is technically a new indication with new efficacy trials, and it will go through its own review. A realistic earliest-possible US commercial availability for the 5% hair-loss formulation is 2028, with meaningful uncertainty in both directions.

What this means for the transplant decision

Clascoterone is not currently a substitute for a hair transplant in patients with established pattern loss. It's a protective and modestly regenerative treatment for follicles that are still miniaturizing but not yet fully lost. The right analogy is finasteride or dutasteride today: it slows the disease and improves the appearance of hair that's still there, but it doesn't fill in bald areas that are actually bald.

The interesting scenario for anyone considering a transplant in Colombia or elsewhere is a combined regimen once clascoterone is available. Transplanted hair is DHT-resistant by donor selection, so DHT-blockers don't affect it. But your native non-transplanted hair keeps aging on its normal androgenetic clock. A well-planned transplant protected by long-term clascoterone (or finasteride, or dutasteride) will hold cosmetically better and longer than a transplant without medication maintenance. For patients who don't tolerate oral 5-AR inhibitors and don't want to gamble on compounded topicals with variable absorption, clascoterone is the option they haven't had.

Practical bottom line

Clascoterone's Phase 3 data is strong enough that most dermatologists watching the pipeline now expect approval as a base case, with the main uncertainty being timing and pricing. If you have pattern loss that's actively progressing and you've been avoiding oral finasteride because of side-effect concerns, the reasonable move is: keep whatever you're doing now (topical minoxidil at minimum), track your loss trajectory carefully, and reassess in 6–12 months as FDA filing progresses. If you're already considering a transplant, don't defer the decision on clascoterone timing alone — but do plan on adding it as maintenance once it's available.

Frequently asked questions

Is clascoterone FDA-approved for hair loss?

Not yet. Cosmo Pharmaceuticals plans to file for FDA approval in early 2027 based on the completed Phase 3 SCALP 1 and SCALP 2 program plus 12-month safety data announced in April 2026. FDA review for a new indication of an already-approved molecule (clascoterone was approved for acne as Winlevi in 2020) typically takes 10–12 months, so a realistic earliest commercial availability for the 5% AGA formulation is 2028.

Can I use Winlevi (clascoterone 1% for acne) on my scalp instead?

The concentration and formulation are different. Winlevi is 1% clascoterone in a cream base designed for facial acne. The AGA formulation is 5% in a solution base designed for scalp application. Compounding pharmacies can produce higher-concentration versions off-label, but you're then relying on that pharmacy's specific compounding rather than the exact formulation Cosmo studied. Speak with a dermatologist about whether off-label use makes sense in your situation.

Is clascoterone safer than oral finasteride?

In the SCALP Phase 3 trials, systemic side effects (sexual, mood, endocrine) were not significantly different from placebo. The molecule breaks down rapidly once absorbed and the parent drug barely enters circulation. That's a fundamentally different exposure profile from oral finasteride, which produces sustained systemic 5-alpha reductase inhibition. Local scalp irritation was the most common side effect and was mild in most patients.

Can women use clascoterone for hair loss?

The Phase 3 program was in men only, so any female use will initially be off-label or dependent on Cosmo running separate female trials. The mechanism — a topical androgen receptor blocker with no measurable systemic exposure — is unusually well suited to women with androgen-mediated hair loss patterns, who have historically been locked out of oral 5-AR inhibitors because of teratogenicity risk. If approved, clascoterone would be a significant addition to female hair-loss medicine.

How does clascoterone compare to PP405?

Different mechanisms, different development stages. Clascoterone is a topical DHT blocker with completed Phase 3 trials and FDA filing planned for early 2027. PP405 is a topical follicle stem-cell activator with completed Phase 2a data and Phase 3 planned for 2026. Clascoterone is further along and lower-risk on the clinical timeline; PP405 is a more novel mechanism but earlier stage. If both eventually reach approval, they would likely be combined in the same regimen, since they address different points in the disease process.

Will clascoterone replace the need for a hair transplant?

No, in the same sense that finasteride and minoxidil don't replace the need for a transplant. Anti-androgen therapies protect and modestly regenerate follicles that are still miniaturizing but not yet fully lost. They don't restore hair to zones that are fully bald. Clascoterone will likely play the maintenance role after a transplant — protecting native non-transplanted hair from continued miniaturization — rather than eliminating the surgical option.